Search Results - "Hu, Mimi"

Hypercalcemia of Malignancy by Hu, Mimi I.

“…Hypercalcemia of malignancy (HCM) is considered an oncologic emergency associated with significant symptom burden and increased comorbid conditions and…”
Get full text

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study by Subbiah, Vivek, Hu, Mimi I, Wirth, Lori J, Schuler, Martin, Mansfield, Aaron S, Curigliano, Giuseppe, Brose, Marcia S, Zhu, Viola W, Leboulleux, Sophie, Bowles, Daniel W, Baik, Christina S, Adkins, Douglas, Keam, Bhumsuk, Matos, Ignacio, Garralda, Elena, Gainor, Justin F, Lopes, Gilberto, Lin, Chia-Chi, Godbert, Yann, Sarker, Debashis, Miller, Stephen G, Clifford, Corinne, Zhang, Hui, Turner, Christopher D, Taylor, Matthew H

“…Oncogenic alterations in RET represent important therapeutic targets in thyroid cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a…”
Get full text

Hypercalcemia and cancer: Differential diagnosis and treatment by Zagzag, Jonathan, Hu, Mimi I., Fisher, Sarah B., Perrier, Nancy D.

“…Incidentally detected hypercalcemia usually presents in an indolent manner and is most likely caused by primary hyperparathyroidism. In contrast, hypercalcemia…”
Get full text

Medullary thyroid carcinoma by Jaber, Tania, Dadu, Ramona, Hu, Mimi I.

“…Purpose of review To summarize recent developments in the diagnosis and management of patients with medullary thyroid cancer (MTC), with a focus on…”
Get full text

Adverse events associated with bone-directed therapies in patients with cancer by Jara, Mark A., Varghese, Jeena, Hu, Mimi I.

“…Bone metastatic disease may lead to serious adverse events in patients with cancer. Bone-directed therapies, including bisphosphonates such as pamidronate and…”
Get full text

Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline by El-Hajj Fuleihan, Ghada, Clines, Gregory A, Hu, Mimi I, Marcocci, Claudio, Murad, M Hassan, Piggott, Thomas, Van Poznak, Catherine, Wu, Joy Y, Drake, Matthew T

“…Abstract Background Hypercalcemia of malignancy (HCM) is the most common metabolic complication of malignancies, but its incidence may be declining due to…”
Get full text

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions by Hamidi, Sarah, Hu, Mimi I.

“…•Non-selective multikinase inhibitors have limited efficacy in RET-altered thyroid cancers, and significant off-target toxicities.•Selpercatinib and…”
Get full text

Letter to the Editor: ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma by Alsharif, Omar, Panella, Timothy, Nodit, Laurentia, Hu, Mimi I

Get more information

Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns by Nguyen, Ha, Shah, Komal, Waguespack, Steven G, Hu, Mimi I, Habra, Mouhammed Amir, Cabanillas, Maria E, Busaidy, Naifa L, Bassett, Roland, Zhou, Shouhao, Iyer, Priyanka C, Simmons, Garrett, Kaya, Diana, Pitteloud, Marie, Subudhi, Sumit K, Diab, Adi, Dadu, Ramona

“…Data on the diagnosis, natural course and management of immune checkpoint inhibitor (ICI)-related hypophysitis (irH) are limited. We propose this study to…”
Get full text

Precision Targeted Therapy with BLU-667 for RET -Driven Cancers by Subbiah, Vivek, Gainor, Justin F, Rahal, Rami, Brubaker, Jason D, Kim, Joseph L, Maynard, Michelle, Hu, Wei, Cao, Qiongfang, Sheets, Michael P, Wilson, Douglas, Wilson, Kevin J, DiPietro, Lucian, Fleming, Paul, Palmer, Michael, Hu, Mimi I, Wirth, Lori, Brose, Marcia S, Ou, Sai-Hong Ignatius, Taylor, Matthew, Garralda, Elena, Miller, Stephen, Wolf, Beni, Lengauer, Christoph, Guzi, Timothy, Evans, Erica K

“…The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer…”
Get more information

Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules by Hu, Mimi I, Waguespack, Steven G, Dosiou, Chrysoula, Ladenson, Paul W, Livhits, Masha J, Wirth, Lori J, Sadow, Peter M, Krane, Jeffrey F, Stack, Brendan C, Zafereo, Mark E, Ali, Syed Z, Weitzman, Steven P, Hao, Yangyang, Babiarz, Joshua E, Kennedy, Giulia C, Kloos, Richard T

“…Abstract Context Broad genomic analyses among thyroid histologies have been described from relatively small cohorts. Objective Investigate the molecular…”
Get full text

Reply to Letter to the Editor regarding “Decreased utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer” by Maniakas, Anastasios, Hu, Mimi I., Gunn, G. Brandon, Zafereo, Mark

Get full text

RET kinase inhibitors for RET-altered thyroid cancers by Vodopivec, Danica M., Hu, Mimi I.

“…Precision oncology has opened a new era in cancer treatment focused on targeting specific cellular pathways directly involved in tumorigenesis. The…”
Get full text

Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance by Hamidi, Sarah, Hofmann, Marie-Claude, Iyer, Priyanka C, Cabanillas, Maria E, Hu, Mimi I, Busaidy, Naifa L, Dadu, Ramona

“…The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a…”
Get full text

Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat—and With Which Drug—Those Are the Questions by Cabanillas, Maria E, Hu, Mimi I, Jimenez, Camilo

“…Context: Medullary thyroid cancer (MTC) is a rare form of thyroid cancer comprising approximately 4% of all thyroid cancers. The majority of patients have a…”
Get full text

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET -mutant medullary thyroid cancer by Wirth, Lori J, Brose, Marcia S, Elisei, Rossella, Capdevila, Jaume, Hoff, Ana O, Hu, Mimi I, Tahara, Makoto, Robinson, Bruce, Gao, Ming, Xia, Meng, Maeda, Patricia, Sherman, Eric

“…Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active kinase inhibitor. In the phase I/II trial, selpercatinib…”
Get full text

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study by Subbiah, Vivek, Hu, Mimi I, Mansfield, Aaron S, Taylor, Matthew H, Schuler, Martin, Zhu, Viola W, Hadoux, Julien, Curigliano, Giuseppe, Wirth, Lori, Gainor, Justin F, Alonso, Guzman, Adkins, Douglas, Godbert, Yann, Ahn, Myung-Ju, Cassier, Philippe A, Cho, Byoung Chul, Lin, Chia-Chi, Zalutskaya, Alena, Barata, Teresa, Trask, Peter, Scalori, Astrid, Bordogna, Walter, Heinzmann, Sebastian, Brose, Marcia S

“…Rearranged during transfection ( ) alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study…”
Get more information

Genetic profiling as a clinical tool in advanced parathyroid carcinoma by Kutahyalioglu, Merve, Nguyen, Ha T., Kwatampora, Lily, Clarke, Callisia, Silva, Angelica, Ibrahim, Eiman, Waguespack, Steven G., Cabanillas, Maria E., Jimenez, Camilo, Hu, Mimi I., Sherman, Steven I., Kopetz, Scott, Broaddus, Russell, Dadu, Ramona, Wanland, Kacey, Williams, Michelle, Zafereo, Mark, Perrier, Nancy, Busaidy, Naifa L.

“…Context Parathyroid carcinoma (PC) is a rare endocrine malignancy with no approved systemic therapies for unresectable locally invasive or distant metastatic…”
Get full text

Denosumab: a new agent in the management of hypercalcemia of malignancy by Thosani, Sonali, Hu, Mimi I

“…Hypercalcemia of malignancy is an oncologic emergency due to tumoral factors that stimulate osteoclast-mediated bone resorption. It requires a combination of…”
Get full text

Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma by Deschler-Baier, Barbara, Konda, Bhavana, Massarelli, Erminia, Hu, Mimi I, Wirth, Lori J, Xu, Xiaojian, Wright, Jennifer, Clifton-Bligh, Roderick J

“…Activating RET alterations have been reported in a variety of solid tumors, including pheochromocytoma where they occur both sporadically and as part of…”
Get full text